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Placebo treatments can be used to elicit many different physiological responses; 
however, the underlying mechanisms responsible remain unclear.  Recent research has 
shown the possibility of a genetic influence on the placebo response in patients with 
mood disorders.  In this study, we attempted to establish a similar relationship in healthy 
college-aged students.  Force production was measured by isometric knee extension of 
the quadriceps muscles using maximum voluntary contractions (MVC).  Subjects were 
given placebo treatments disguised as an undisclosed sports supplement with the 
information that the supplement was previously shown to provide immediate strength 
improvements following ingestion.  Subject DNA was genotyped for two genetic 
polymorphisms, tryptophan hydroxylase-2 (TPH2) and monoamine oxidase A (MAO-A).  
These particular polymorphisms were chosen for study based on previous research and 
their possible relationships to athletic performance.  Results showed a 4.4% improvement 
in peak force with the ingestion of the placebo for both men and women (p < 0.05).  We 
also found that the average placebo effect was similar for both genders (3.37% 
improvement in males, 7.47% in females).  Neither polymorphism displayed a significant 
effect on the presence of the placebo response.  We concluded that while a placebo 
response was evident with MVC isometric force production, TPH2 and MAO-A were not 
likely to be responsible for the effect. 
 
  
Chapter I: Introduction 
The most common protocol for proving the efficacy of a new drug or supplement 
is to design a randomized, double-blind study that allows the effects of the drug or 
supplement to be compared to those of a placebo.  If the drug or supplement provides 
more positive or beneficial results than the placebo, the drug or supplement is said to be 
effective.  Until recently, placebo effects have always been attributed to biological or 
psychological factors yet to be fully identified (24).  However, recent research has 
evaluated specific genetic polymorphisms predisposing responders to placebo treatments. 
Furmark et al. monitored amygdala response in participants with social anxiety disorder 
(SAD) (6).  The amygdala is the portion of the brain that monitors and processes 
emotions.  Decreased activity in the amygdala is associated with low amounts of stress; 
SAD patients strive to achieve this through medications and therapy.  Furmark et al. 
observed the greatest placebo response with subjects who carried the G allele in the 
tryptophan hydroxylase-2 (TPH2) gene (6).  These same subjects experience a naturally 
lower amount of amygdala activity in the brain as a result of their genotype.  Similarly, 
Leuchter et al. studied patients diagnosed with major depressive disorder (MDD) and 
found that subjects with a moderate or intermediate rate of monoamine oxidase A (MAO-
A) enzymatic activity experienced the greatest degree of placebo response (11).  MAO-A 
is an enzyme that facilitates the catabolism of norepinephrine, a process that can lead to 
symptom relief for MDD patients.  The intermediate rate of enyzme activity was found in 
females with the heterozygous G/T expression of the gene.  Because of the sex-linked 
nature of this polymorphism, males can only code for the high-rate expression (G allele) 




Research has shown that placebos are capable of producing similar or greater 
effects than many sports supplements.  Beedie et al. demonstrated that athletes given a 
hypothetical ergogenic aid coupled with positive information regarding the substance 
maintained sprint times in a repeat-sprint trial of 30 meters, whereas negative information 
led to trial times 2% slower than baseline values (1).  Clark et al. evaluated differences in 
power output during 40-km cycling time trials when subjects were given a placebo versus 
a carbohydrate supplement dissolved into a drink (4).  Subjects in each supplement group 
were further divided into three subgroups based on what each subgroup was instructed 
about their particular drink contents: told carbohydrate, told placebo, and not told.  
Subjects who were given the placebo but were told they received the carbohydrate 
beverage experienced an average of 7% improvement in power, the greatest change out 
of any subgroup.  Pollo et al. showed that the perception of taking an ergogenic aid could 
increase quadriceps muscle performance and decrease muscle fatigue (17).  Two groups 
were used: a supplement group and a control group.  Subjects were not blinded to which 
group they were assigned to; however, neither group actually received any form of an 
ergogenic aid.  Muscle performance was assessed over the course of four trials as the 
number of repetitions generated by the quadriceps at 60% of 1RM and the total work 
performed in each session.  Without informing the subjects, trials 2 and 3 were actually 
performed at 45% of 1RM to further the deception of the efficacy of the ergogenic agent.  
Compared with baseline data, the supplement group showed an improvement of 22%.  
Countless other studies have shown significant placebo responses to ergogenic aids; 
however, the potential genetic effect on the placebo response to an ergogenic aid has not 




to determine if a genetic link exists between a specific genetic polymorphism and the 
ergogenic response to a placebo. 
More specifically, we seek to determine if a genetic link exists between a person’s 
susceptibility to a placebo purported to be an ergogenic aid and either the monoamine 
oxidase A or the tryptophan hydroxylase-2 gene polymorphisms.  These polymorphisms 
have been chosen because of the promising data shown previously (6, 11).  Furthermore, 
because of their relations to emotional processing and pain relief, both polymorphisms 
may play a role in athletic performance.  The implications of establishing such a 
connection are considerable.  Particularly, if certain people are genetically inclined to 
react to a placebo, the “gold standard” of drug testing with comparison to a placebo may 
no longer apply without prior genotype screening of participants.  Also, if medical 
conditions can be treated and alleviated with a placebo, a moral issue arises of whether or 
not to lie to a patient about a treatment.  The two major studies focusing on genetics and 
the placebo response that were previously mentioned focused on patients with mood 
disorders.  To date, no study has yet examined the placebo effect in healthy subjects or in 
conditions where the placebo is supposed to elicit improvements in physical performance.  
Therefore, this study will compare the maximum voluntary contractions (MVC) of the 
quadriceps muscles in physically active subjects on two separate occasions – with and 
without ingestion of a supposed performance-enhancing supplement.  Results will then be 
characterized by the genotypes of the subjects to determine if there is a genetic link. 
 
Chapter II: Background 
I. Eliciting placebo response through deception in athletic performance 
Intervention Author/Year Sample 
Size 
Training 
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 Placebos have been shown to enhance performance for a variety of athletic 
performances.  Placebo treatments can improve endurance performance time trials with 
both running and cycling (1, 14).  Strength performance can also improve when subjects 
believe that a supplement will benefit their power output (2, 4, 5, 8, 12, 17). Maganaris et 
al. found that giving placebo steroid treatments to elite weightlifters collectively 




mean power in a 10km cycling time trial increased 1.3% when subjects believed they had 
ingested 4.5 mg/kg of caffeine and 3.1% when subjects believed they had ingested 9.0 
mg/kg of caffeine (2).  Clark et al. found an improvement of 4.3% in mean cycling power 
during a 40km time trial in response to a placebo carbohydrate beverage (4). 
Interventions in these studies usually inform the subjects that one of several 
widely accepted ergogenic aids – such as steroids, caffeine, sodium bicarbonate, 
carbohydrate, etc. – will be given to improve athletic performance.  It seems that the 
greatest effects are also seen when subjects receive positive information or reinforcement 
regarding the supplement (1, 8).  Conversely, negative information can lead to a negative 
impact on performance (1).  Very little data has been seen on the ability to elicit a 
placebo effect using a supplement that is unfamiliar to subjects.  Using aids that are 
familiar to subjects may allow for preconceived notions regarding such supplements to 
dominate the subjects’ response to the placebo treatment and thus contribute to the high 
degree of variability seen in placebo studies.  By using an unknown sport supplement, 
every subject will begin at baseline knowledge and will hopefully negate the effects of 
prior beliefs. 
 Several other contributors may influence the magnitude of placebo response, 
including sample size, subject training status, and method of performance testing.  In 
most cases, a larger sample size seems to relatively magnify the percent of change for 
placebo treatments (4, 8, 17).  Perhaps a larger sample size is needed to clearly identify if 
a placebo response exists.  Also, the differences in training status may greatly affect the 
outcome of each study.  In several studies, sub-elite athletes were used.  When compared 




allowing for a greater chance of variability and change in performance measures.  
Finally, the procedures utilized in these studies are not standardized.  It is very difficult to 
compare performance measures for strength improvements in 1RM to 40km cycling time 
trials.  Furthermore, our protocol will utilize untrained, recreationally active students and 
will use force production strength measures to quantify the degree of placebo response.  
By doing so, it will be much easier to compare any performance improvements seen to 
existing data and will help with interpreting the results of testing. 
 
II. Genetic determinants of placebo response 
Author/Year Disorder Treatment Effect of Treatment Genetic Polymorphism 
Identified 
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 A genetic polymorphism exists when a particular gene can be clearly expressed 
by two or more phenotypes or morphological traits.  Each polymorphism can be 
identified according to the coding sequence found on DNA in the region specific to each 
particular gene.  In two separate studies, patients with mood disorders that possessed 
specific alleles in two known genetic polymorphisms experienced a greater degree of 




polymorphisms in question were the G-703T polymorphism of the tryptophan 
hydroxylase-2 (TPH2) gene promoter in patients with social anxiety disorder and GT 
polymorphism of the monoamine oxidase A (MAO-A) enzyme.  Furmark et al. studied 
subjects that were diagnosed with social anxiety disorder (SAD), which is characterized 
by anxiety and fear from the judgment of others (6).  The symptoms of SAD can be 
treated with medication to alleviate anxiety by reducing stress-related activity in the 
amygdala of the brain.  Placebo treatments, disguised as SAD medications, have also 
been shown successful in treating SAD.  Patients who carry the T allele in the TPH2 gene 
tend to naturally display a higher amount of amygdala activity then patients who are 
homozygous for the G allele.  It was observed that patients homozygous for the G allele 
demonstrated the greatest response to placebo treatments with regard to SAD symptom 
alleviation.  Leuchter et al. evaluated subjects diagnosed with major depressive disorder 
(MDD), a mood disorder characterized by chronic depression associated with symptoms 
of sadness, loss, anger, or frustration (11).  Monoamine oxidase A (MAO-A) is an 
enzyme that facilitates the catabolism of norepinephrine.  The sex-linked gene that codes 
for MAO-A determines the rate of enzymatic activity: males with a single T allele or 
females with T/T demonstrate the lowest-activity rate; G/T females have a moderate or 
intermediate rate; G males or G/G females show the highest-activity rate.  In patients 
with MDD, the highest activity of MAO-A (G or G/G alleles) showed the lowest 
response to placebo treatments.  The intermediate rate of MAO-A activity, coded by the 
G/T alleles, showed the most promising response to placebo treatments. 
 Current research findings cannot be generalized to a greater population because 




Specifically, it is unknown if genetic polymorphism can influence individuals without 
mood disorders.  Furthermore, it is unknown if these polymorphisms would influence the 
placebo response in other situations, such as athletic performance.  Thus the present study 
will look at healthy subjects who are recreationally active to see if a similar genetic link 
can be established for placebo effect. 
 
III. Reliability and validity of knee extension MVC through isometric testing 
Author/Year 
 








14 Handheld dynamometer 0.98 
Rainoldi et al. 
2001 
(18) 
9 Specially designed bed with force 
transducer 
0.70 
Larsson et al. 
2003 
(10) 
20 Isokinetic dynamometer 0.93 
Symons et al. 
2005 
(21) 
19 Biodex 0.91 
Kelin et al. 2008 
(9) 
20 Handheld dynamometer 0.79 
 
 A maximum voluntary contraction (MVC) is the peak force produced by one 
single contraction.  Knee extension isometric MVCs have been accepted as a reliable 
measure of muscular strength.  Most research on the reliability of isometric MVC testing 
has shown a high degree of correlation between trial sessions on different days (3, 10, 20, 
21).  This shows a great amount of repeatability with minimal day-to-day variability in 




 Many factors can contribute to variations and limit correlation.  Maintaining the 
same position for each test repetition is crucial.  Bohannon manually braced each limb 
during testing, which could contribute to intersession variance (3).  Less controllable 
factors such as subject moods or degree of motivation can also add day-to-day 
differences (18).  Kelin et al. evaluated intratester and intersession reliability by utilizing 
three separate testers of varying degrees of experience in using a handheld dynamometer 
(9).  Both intratester and intersession results showed high correlation values and low 
standard error of measurements.  However, it was observed that handheld dynamometers 
were likely to be contraindicated in any instance where the strength of the subject may 
overpower that of the tester.  For example, it was discovered during pilot testing that the 
subjects’ strength in plantar flexion was greater than the testers’ ability to resist the 
motion (9).  This could not be remedied in any way by changing the angle at which the 
test was being administered, so plantar flexion strength could not be evaluated by this 
method.  Therefore, the most ideal method for using these dynamometers may be to place 
the subjects in a position that offers a greater mechanical advantage to the tester.  Symons 
et al. used a Biodex to test single-session repeatability in older men (21).  The coefficient 
of variation ranged from 8 to 17% for peak torque (21).  The most notable aspect about 
this protocol was the system developed by the tester.  Every subject was given verbal 
instructions regarding the testing procedure.  His or her leg was then moved passively 
through the range of motion.  Once completed, each subject had the opportunity to 
practice the test before the actual recorded test was administered.  Throughout the entire 
protocol, the subject was given consistent encouragement.  In order to standardize this 




every subject.  Verbal feedback regarding specific force data should not be given as it 
could change the subject’s motivation for the next test.  The use of the Biodex also limits 
the variability created by using the handheld dynamometers by facilitating reproducible 
setups. 
 
IV. Proposed mechanisms for the placebo effect 
Author/Year Treatment type Proposed mechanism 
Voudouris et al. 1989 
(22) 
Analgesic cream Classical conditioning 
Voudouris et al. 1990 
(23) 
Analgesic cream Classical conditioning 
Montgomery and Kirsch 1996 
(16) 
Topical anesthetic Classical conditioning, 
Expectancy theory 
Mayberg et al. 2002 
(13) 
Antidepressant medication Expectancy theory 
McRae et al. 2004 
(15) 
Transplantation of human 
embryonic dopamine neurons 
in patients with advanced 
Parkinson’s disease 
Expectancy theory 
Wager et al. 2007 
(25) 
Analgesic cream Expectancy theory 
 
 Two main theories have been proposed to explain the psychological mechanism 
for the placebo effect: classical conditioning and expectancy theory.  Classical 
conditioning, as introduced by Ivan Pavlov in 1927, states that a response can be learned 
when the same stimulus is applied repeatedly (19).  When the subject is properly 
conditioned, a conditioned response will occur when the same stimulus is applied.  The 
famous example of classical conditioning, Pavlov’s dogs, demonstrated the dogs’ 
conditioned response (salivating) in response to the stimulus (bell) that had previously 
been associated with the serving of food.  Expectancy theory states that a placebo will 




expectations can result from advertisements, support from credible people (such as 
doctors, scientists, etc.), or referrals made by trusted family or friends. 
 In two separate studies, Voudouris et al. placed subjects into groups to determine 
which theory was responsible for the placebo effect (22, 23).  In the 1989 study, two 
groups of subjects were instructed that an analgesic cream would reduce skin sensitivity 
and block pain (22).  Three trials were established where the pain stimulus was 
incrementally increased until the subject could no longer tolerate the pain.  They were 
then treated with the cream and the stimulus was again applied until it was no longer 
tolerable.  During the second trial, the rate of increment was decreased for group I and 
increased for group II without the subjects’ knowledge to simulate the conditioning 
phase.  Despite the expectancy that the cream would diminish the pain, group II subjects 
showed a decrease in mean pain tolerance as a result of the learning that occurred in trial 
2.  These results were confirmed by the second study published in 1990.  Using a 
different methodology that both separated expectancy and conditioning and combined the 
two, it was found that conditioning alone elicited a greater placebo response than 
expectancy alone (23). 
 Mayberg et al. focused only on the expectancy theory (13).  In treating clinically 
depressed men, half of the men who experienced symptom remission had been given 
placebos (13).  No conditioning was performed on these subjects, but they were clearly 
instructed on how the treatment was supposed to improve mood.  Similarly, McRae et al. 
found that out of the 30 subjects, the 18 that received a sham surgery versus a neuron 




who actually received the transplant (15).  Again, only the expectation that the treatment 
should work was responsible for the outcome. 
 It seem that the literature is unclear whether one theory holds greater 
responsibility than the other.  Stewart-Williams and Podd suggest that perhaps both play 
a key role in facilitating a placebo response (19).  One can also function independently of 
the other, as seen in the studies by Mayberg et al. and McRae et al. (13, 15). 
 Very little research has been conducted on the physiological mechanisms 
surrounding the placebo response.  Wager et al. has shown that despite the lack of a 
pharmacological treatment in placebo pain therapy, a physiological effect can still take 
place (25).  Similar to the body’s response to pain medication, the expectancy of a 
treatment can elicit opioid release that relieves pain.  However, little is known about why 
or how this occurs. 
 
 
Chapter III: Methods 
Subjects. 
 Informed consent was obtained from 54 subjects (34 male, 20 female), aged 18-
22.  Subjects were recreationally active (minimum: 1 bout of exercise per week for 30 
minutes) college students from James Madison University.  Upper level 
Kinesiology/Exercise Science students with prior knowledge of typical supplement 




 Subjects participated in three trials on separate occasions.  The first was a 
familiarization trial.  Subjects were asked to perform a number of maximum voluntary 
contractions (MVC) of the quadriceps muscle using a custom-built muscle function 
device designed at James Madison University.  The test was performed with the subject 
seated upright with the self-reported dominant leg positioned at approximately 70° of 
knee flexion.  Each MVC was held for 3 seconds against the stationary bar, and force 
production was measured from a force transducer for each contraction.  A minimum of 
three repetitions with a maximum of eight were used to determine maximal force output 
for the trial until two numbers were generated within 20N of each other, and the results 
were averaged. 
 The same MVC protocol was applied during the two subsequent treatment trials.  
Prior to each trial, subjects ingested 50 mL of a commercial sports beverage.  On one 




dissolved into the drink.  On the other occasion (control trial), the subject was told that 
the drink did not contain the ergogenic aid.  Nothing was actually dissolved into the drink 
on either day. MVC tests were conducted immediately following ingestion and a 5-min 
warm-up (3mph on treadmill).  The order of the treatment trials was randomly counter-
balanced. 
 To prevent subjects from attempting to research the ergogenic aid thought to be 
used in this study, subjects were informed that the supplement was still in its testing 
phase and was not readily available on the market to consumers. 
 
Genotyping. 
 Blood samples were obtained from each subject during the Familiarization Trial.  
DNA was extracted from whole blood using a Qiagen kit following the manufacturer’s 
protocol (Qiagen, Valencia, California).  DNA samples were sent to the Center for 
Genetic Medicine Research in Washington, DC for genotyping.  Specifically, the 
genotyping was conducted for MAO-A and TPH-2 gene promotor.  Genotyping was 
blinded to subject, treatment, and treatment response. 
MAOA T941G Polymorphism  
To determine the presence of T- or G- allele located at mRNA position 1072 in 
the coding sequence of the MAOA gene (Gene ID: 4128), a PCR product was amplified 
using forward primer 5′-GAC CTT GAC TGC CAA GAT-3′ and reverse primer: 5′-
CTTCTTCTTCCAGAAGGCC-3′ with methods developed by Hotamisligil and 
Breakefield (7). The polymerase chain reaction (PCR) was performed according to the 




volume: 20 µl) contained 50g DNA, Buffer II (40 mM Tris-HCl [pH 8.4], 100 mM KCl, 
3 mM MgCl2, 400 µM dGTP, 400 µM dATP, 400 µM dTTP, 400 µM dCTP, 1U 
AccuPrime Taq DNA Polymerase, thermostable AccuPrime protein, and stabilizers) 
(Invitrogen), 0.1 mM/L of each primer. After the initial denaturation step at 94°C for 2 
min, DNA was amplified in 35 PCR cycles (94°C for 30 sec; 60°C for 30 sec; 68°C for 1 
min). Ten microliters of the PCR product was digested with 3U Fnu IV (New England 
Biolabs, US), analyzed by gel electrophoresis in a 2% agarose gel containing ethidium 
bromide, and visualized under UV light. When a G allele is present, digestion results in 
two fragments of 65 bp whereas the absence of the Fnu IV recognition site (GCNGC) 
leaves the 130-bp PCR product intact. 
TPH2 (-G703T) Polymorphism 
The TPH2 -G703T (rs4570625) is located in the putative transcriptional control 
region of TPH2 (Gene ID: 121278). PCR was performed with the forward primer 5′-
TTTTATGAAAGCCATTACACAT-3′ and the reverse primer 5′-
TTCCACTCTTCCAGTTATTTTA-3′ developed by Furmark et al. (6). The PCR 
amplification mixture (total volume = 20 µl) contained 50g gDNA, Buffer II (40 mM 
Tris-HCl [pH 8.4], 100 mM KCl, 3 mM MgCl2, 400 µM dGTP, 400 µM dATP, 400 µM 
dTTP, 400 µM dCTP, 1U AccuPrime Taq DNA Polymerase, thermostable AccuPrime 
protein, and stabilizers) (Invitrogen), 0.1 mM/L of each primer. Samples were amplified 
using a Thermocycler (GeneAmp PCR system 2720, Applied Biosystems) for 35 cycles. 
After an initial 2 min at 94°C, each subsequent cycle consisted of 30 s at 94°C, 30 s at 
60°C, and 1 min at 68°C. The amplified DNA (10 µl) was digested with the 5U of the 




product was electrophoresed in 2% agarose gels and stained with ethidium bromide. The 
undigested PCR product carries the G variant, whereas the digested product with two 
fragments of 55 and 149 bp contains the T allele. Homozygous genotypes were identified 
by the presence of a single 204 bp band (G/G), or bands of 55 and 149 bp (T/T). The 
heterozygous genotype had three bands: 204, 55, and 149 bp (G/T). 
 
Statistical Analysis. 
 Statistical analyses were performed using the Statistical Package for the Social 
Sciences version 16 (SPSS Inc, Chicago, Illinois).  The placebo effect was quantified as 
the percent difference between the trial in which the subject believed they were ingesting 
the ergogenic aid and the control trial.  Potential differences in the placebo effect were 
compared across genotypes using repeated measures analysis of variance (ANOVA) with 
one within-subjects effect (treatment) and two between-subjects effects (genotype and 
gender).  Post-hoc differences were determined using a t-test with a Bonferroni 
correction.
 
Chapter IV: Results 
Subjects displayed a significant increase in MVC when told they were receiving a 
supplement (P < 0.05) (Figure 4.1). Mean force production for the treatment without the 
supplement was 487 ± 137N while the mean force production for the treatment with the 
perceived supplement was 508 ± 145N. 
Tables 4.1 and 4.2 summarize the percent improvement for the placebo response 
for each genotype by gender.  There was no main effect for gender on the placebo 
response (P > 0.05).  There was a 3.37% increase in force production for males and 
7.47% for females with the perceived supplement.  Furthermore, there was no main effect 
for genotype nor a genotype x treatment interaction for either the MAO-A or TPH2 
polymorphisms (P > 0.05), suggesting that neither polymorphism impacted the 
magnitude of the placebo response in this sample of subjects. 
 
Figure 4.1: Force production (* denotes significance at p < 0.05) 
 





Gender Genotype Mean Std. Deviation N 
G 4.6536 10.93301 8 
T 2.9713 12.87901 26 
Male 
Total 3.3672 12.31007 34 
G 4.4591 13.07367 4 
T 8.2193 10.22442 16 
Female 
Total 7.4672 10.57825 20 
G 4.5888 11.07650 12 
T 4.9706 12.08465 42 
Total 
Total 4.8857 11.76702 54 
 
Table 4.2: Percent Improvement for the placebo for TPH2 
Gender Genotype Mean Std. Deviation N 
GG 3.5772 12.84906 31 
GT 1.1968 4.01843 3 
Male 
Total 3.3672 12.31007 34 
GG 7.3231 10.99320 17 
GT 8.2839 9.75005 3 
Female 
Total 7.4672 10.57825 20 
GG 4.9039 12.23930 48 
GT 4.9706 12.08465 6 
Total 
Total 4.8857 11.76702 54 
 
Chapter V: Discussion 
The primary finding of the present study is that MVC force production was 
elevated by 4.4% when subjects believed they had ingested an ergogenic aid.  This 
placebo effect reaffirms that supplement and drug efficacy studies should utilize double-
blind protocols.  If subjects are not blinded to which intervention they are receiving, it 
would be hard to prove that any given substance is more effective than not giving any 
substance at all.  Also, by limiting the subjects’ prior knowledge about the sport 
supplement, the tester was able to provide the same information regarding the supplement 
and its supposed effects to every subject, likely increasing the impact of the placebo 
response. 
The increase in force production also confirms that a placebo response can be 
demonstrated with maximal strength testing.  The change of +4.4% in maximal force 
production is consistent with both the 3.8% improvement in 1RM demonstrated by 
Maganaris et al. and 4.3% increase in mean power during a 40km cycling time trial by 
Clark et al. (4, 12).  The study conducted by Kalasountas et al. was most similar in 
subjects and methods to our study (8).  Specifically, the authors also examined untrained, 
recreationally active college-aged students as subjects, and performance measures were 
strength measurements.  Kalasountas et al. also included a treatment/no-treatment group 
similar to the intervention protocol we used (8).  However, our findings showed a much 
smaller improvement in change in force (4.4% versus 19.6%).  This could be due to the 
use of 1RM bench press and leg press to evaluate strength changes in the study by 





Gender did not impact the magnitude of the placebo effect; both males and 
females demonstrated a similar degree of placebo response.  Males experienced a 3.39% 
increase while females experienced a 6.70% increase in force production.  These changes 
were not significantly different from one another.  Therefore, future placebo studies need 
not discriminate potential subjects based on gender. 
Neither of the genetic polymorphisms selected for this study (TPH2 and MAO-A) 
influenced the placebo response to a perceived sports supplement.  These two 
polymorphisms selected were chosen based on the promising results seen in previous 
studies and the possibility of their impact on athletic performance (6, 11).  Furmark et al. 
observed the greatest placebo response with SAD patients who carried the G allele in the 
TPH2 gene (6).  As a result of their genotype, these same subjects experience a naturally 
lower amount of amygdala activity in the brain, which leads to lower stress levels.  In the 
study by Leuchter et al., MDD patients with a moderate or intermediate rate of MAO-A 
enzymatic activity experienced the greatest degree of placebo response (11).  This trait 
was found in females with the heterozygous G/T expression of the gene.  Because of the 
sex-linked nature of this polymorphism, males can only code for the high-rate expression 
(G allele) or low-rate activity (T allele).  In this study, subjects who carried either the G 
allele in the TPH2 gene or the G/T expression of the MAO-A gene or both did not 
experience a significantly higher magnitude of placebo response than the subjects who 
possessed other gene expressions.  However, these genetic links may only be evident in 
patients with mood disorders.  The underlying conditions of social anxiety disorder or 
major depressive disorder may have influenced the findings of the previous studies, and 




quantifying a psychological response to a treatment such as “alleviating anxiety” may be 
more subjective than measuring force production.  It is difficult to maintain consistency 
in evaluation when subjects self-report the degree of their symptom resolution, and the 
data results may not be comparable to the results of our study. 
There were several limitations to this study that should be noted.  First, the sample 
size may not have been large enough to observe significant differences between genetic 
groups.  With genetic research, larger sample sizes are needed because the testing pool 
quickly diminishes when subjects are divided into sub-groups based on their genetic 
characteristics.  However, there was no trend present to suggest that a larger sample size 
may have led to any significant findings (MAO-A p = 0.77; TPH2 p = 0.74).  The second 
limitation was that the polymorphisms selected for this study might have limited the 
scope of possibility.  TPH2 and MAO-A have been shown to be influential in patients 
with mood disorders; however, they may not exhibit the same influence in healthy 
subjects.  A third limitation was the use of isometric force as the measure of force 
production.  Isometric force does not translate to other methods of force production 
because of the lack of movement through the joint’s range of motion.  Also, strength tests 
may not fatigue the subject enough to elicit a genetically-influenced placebo response.  
Endurance training protocols that are longer in duration may allow more time for the 
deception to affect the subject psychologically.  Isometric testing was used in this study 
because of its simplicity and low daily variability.  Data on the reliability of MVC force 
production on a day-to-day basis indicates a high degree of reproducibility (3, 10, 20, 21).  




with such a simple protocol, there is a lack of genetic effect associated with this particular 
protocol. 
 In summary, a placebo response can be elicited with MVC force production of the 
quadriceps.  This can be seen in both males and females.  However, our findings suggest 
that the TPH2 and MAO-A gene polymorphisms do not influence the likelihood of a 
placebo response.  Future studies should consider other polymorphisms that are not 
influenced by the presence of mood disorders or other underlying conditions.  






Consent to Participate in Research 
Identification of Investigators & Purpose of Study   
You are being asked to participate in a research study conducted by Jennifer Wu from 
James Madison University.  The purpose of this study is to determine if genetics affect 
the training response obtained by ingestion of a specific supplement. 
 
Potential Risks & Benefits 
If you choose to participate in this study, you will perform three separate trials of a 
maximum voluntary contraction of the thigh muscle.  The investigator perceives the 
following are possible risks arising from your participation in the study: nausea, 
discomfort, dizziness, and in rare occurrences, heart attack, stroke or death. However, 
you were chosen for this study because of your low risk for these occurrences. In healthy 
individuals, the risk of death during vigorous exercise has been estimated at 1 death per 
year for every 18,000 individuals. 
 
Potential benefits from participation in this study include:  
1) Helping with research that may improve the effectiveness of supplementation by 
targeting people for whom it will be most effective. 
2) Knowledge of your maximal voluntary contraction 






Should you decide to participate in this research study, you will be asked to sign this 
consent form once all of your questions have been answered to your satisfaction.  This 
study consists of three separate trials of a maximum voluntary contraction of the thigh 
muscle.  All testing will occur in Godwin Hall, room 209, on the campus of James 
Madison University.  Furthermore, you will be asked to regulate your diet intake 
according to specific guidelines prior to every testing session. All tests will be separated 
by at least 48 hours, so that you will be tested three times over a two to three week 
period, for a total of approximately three hours of testing. A blood draw will also be 
taken at the first testing session for the purpose of genotyping. 
 
Maximum voluntary contraction: These three test sessions will be performed at the same 
time of day each time. You will be asked to refrain from food and beverages (except 
water) for two hours prior to these tests. In addition, you will need to refrain from 
consumption of caffeine-containing beverages (coffee, tea, cola drinks, cocoa) for 24 
hours prior to the test. During these three test sessions, you will maximally contract your 
thigh muscle against an unmoving knee extension bar. This test will be performed three 
times during each session, and the average score will be calculated for each session. Ten 
minutes prior to each test, you will ingest an 8 oz. portion of a popular sports beverage 
either with the supplement dissolved into the beverage or without the supplement. 
Between test preparation and completion of these exercise tests, each test should take 





Blood Sampling: We will obtain about 5 ml of blood (about 1 teaspoon) prior to the first 
test session in order to extract DNA and determine specific genotypes.  These blood 
samples will be obtained from an arm vein.  
 
DNA Sampling: We will extract a sample of your DNA from your blood sample.  The 
DNA will be stored in our laboratory, but the sample will be coded so that no one except 
the investigators can detect which sample is yours. The DNA testing will involve 
determining your sequence of DNA for a specific gene that may be related to the 
effectiveness of the supplement. The results of this genetic testing will only be available 
to the primary investigator and you. These results will not be made public and will be 
stored in a locked file cabinet.  Your samples and data will be discarded after a five year 
period; or earlier if requested by you. 
 
Confidentiality  
The results of this research will be presented at conferences and published in exercise 
science journals.  The results of this project will be coded in such a way that your identity 
will not be attached to the final form of this study.  The researcher retains the right to use 
and publish non-identifiable data.  However, you can ask that your data be removed from 
the study at any point prior to presentation and publication.  While individual responses 
are confidential, aggregate data will be presented representing averages or generalizations 
about the responses as a whole.  All data will be stored in a secure location accessible 





Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without consequences of 
any kind.  Your right to withdraw includes the right to request that your DNA and blood 
samples be discarded at any time.  
 
Questions 
If you have questions or concerns during the time of your participation in this study, or 
after its completion or you would like to receive a copy of the final aggregate results of 
this study, please contact: Christopher J. Womack, Ph.D. at womackcx@jmu.edu or by 
phone at 540-568-6515. 
Questions about Your Rights as a Research Subject 
Dr. David Cockley  
Chair, Institutional Review Board 




Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 






   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   






AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire 
Assess your health status by marking all true statements 
 
History 
You have had: 
   a heart attack 
   heart surgery 
   cardiac catheterization 
   coronary angioplasty (PTCA) 
   pacemaker/implantable cardiac 
   defibrillator/rhythm disturbance 
   heart valve disease 
   heart failure 
   heart transplantation 
   congenital heart disease 
 
Symptoms 
   You experience chest discomfort with exertion 
   You experience unreasonable breathlessness 
   You experience dizziness, fainting, or blackouts 
   You take heart medications 
 
If you marked any of these statements 
in this section, consult your physician 
or other appropriate health care 
provider before engaging in exercise.  
You may need to use a facility with a 




Other Health Issues 
   You have diabetes 
   You have asthma or other lung disease 
   You have burning or cramping sensation in your lower  
   legs when walking short distances 
   You have musculoskeletal problems that limit your  
   physical activity 
   You have concerns about the safety of exercise 
   You take prescription medication(s) 
 
Cardiovascular risk factors 
   You are a man older than 45 years 
   You are a woman older than 55 years, have had a  
   hysterectomy, or are postmenopausal 
   You smoke, or quit smoking within the previous 6 months 
   Your blood pressure is > 140/90 mmHg 
   You do not know your blood pressure 
   You take blood pressure medication 
   Your blood cholesterol level is > 200 mg/dl 
   You do not know your cholesterol level 
   You have a close blood relative who had a heart attack or 
   heart surgery before age 55 (father or brother) or age 65 
       (mother or sister) 
If you marked two or more of the 
statements in this section, you 
should consult your physician or 
other appropriate health care 
provider before engaging in 
exercise.  You might benefit from 
using a facility with a 
professionally qualified exercise 





   You are physically inactive (i.e. you get < 30 minutes of  
   physical activity on at least 3 days of the week) 
   You have a BMI > 30 kgm2 or waist circumference 
   > 102 cm (men) or > 88 cm (women) 
 
   None of the above 
You should be able to exercise safely 
without consulting your physician or 
other appropriate health care provider 
in a self-guided program or almost any 






Subject Prescreening Information 
Please Complete the Following: 
Gender:  Male     Female    (circle one) 
Age (yrs):  
Height (inches): 
Weight (lbs):  
Average Exercise Habits over the Past 2 Months: 
Avg. # days of exercise per week: 
Avg. amount of time per bout of exercise: 
Do you have a muscle or joint injury that precludes the completion of the exercise 
protocol?  Explain. 
 
Do you currently use medications for relief of pain and/or soreness?  Explain. 
 
Do you have a blood clotting disorder (haemophilia, thrombocytopenia, etc)? 
 
Do you currently use blood-thinning medications (Coumadin, etc)? 
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